Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Lithium Ion. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4534831 | 0.91 | — | — | |
| Lithium Ion SCHEMBL180714 | 0.91 | — | — | |
| Sodium Azide SCHEMBL123 | 0.91 | — | — | |
| SCHEMBL31744312 | 0.91 | CA1 (1.00) | — | |
| SCHEMBL3903787 | 0.91 | — | — | |
| Ammonia Solution, Strong SCHEMBL10346943 | 0.83 | — | — | |
| Potassium Ion SCHEMBL11607652 | 0.83 | — | — | |
| SCHEMBL1473179 | 0.83 | — | — | |
| Water SCHEMBL11762204 | 0.83 | — | — | |
| SCHEMBL16531899 | 0.83 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090227781-A1 | Glycolipid Derivative and Drug Containing the Same as Active Component | JAPAN AS REPRESENTED BY PRESIDENT OF NATIONAL CENTER OF NEUROLOGY AND PSYCHIATRY (JP) | 2009-09-10 | — | — | US | disclosed |
| EP-1905766-A1 | GLYCOLIPID DERIVATIVE AND THERAPEUTIC AGENT COMPRISING THE SAME AS ACTIVE INGREDIENT | Japan as represented by President of National Center of Neurology and Psychiatry (JP) | 2008-04-02 | — | — | EP | disclosed |